It's been a year since we wrote about efforts by Proteus Biomedical and Novartis to embed computers and sensors inside drugs and devices to monitor (in real-time) when a patient takes a drug and how they respond to it.
Last week Novartis announced plans to seek regulatory approval within 18 months. Initially, Novartis will use the technology to monitor transplant recipients, in conjunction with one of its existing drugs.
The chips get activated by the patient's stomach acid and will send biometric data that gauges the drug's effectiveness via Bluetooth. For a look at how Proteus' Raisin technology works, take a look at this article.
While Proteus and Novartis are giddy with excitement over the vast therapeutic and revenue opportunities that they see, there are plenty of people who worry about conspiracies and much more sinister happenings.
What do you think - is this a huge step forward for medicine or a huge step backwards for mankind?
ForeignExchange Translations provides specialized medical translation and software localization services to drug and device companies. Contact us to learn more.
Categories: medical devices